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Introduction
Non-lethal tools are needed for the control of over-
abundant wildlife populations in settings in which
traditional management methods, such as regulated
sport hunting, cannot be used because of legal prohi-
bitions or safety concerns. The development and use
of safe, effective, and humane reproductive inhibi-
tors may provide a partial solution to the problem of
overabundant populations of deer and other wildlife
in situations in which hunting is not an option.
Reproductive inhibitors must be tailored to the
physiology of the target species, as no contraceptive
agent is effective, practical, and appropriate for use
in all species.1
GonaCon
TM
Immunocontraceptive Vaccine is a
highly effective contraceptive agent that prevents
pregnancy in white-tailed deer (Odocoileus virgini-
anus),2 elk (Cervus elaphus),3 wild horses (Equus cabal-
lus),4,5 domestic and feral swine (Sus scrofa),6–8 bison
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Problem
An effective, single-injection, multi-year, GnRH contraceptive agent
is needed to control reproduction in overabundant white-tailed deer
populations.
Method of study
Two GnRH conjugates, GonaCon
TM
(GnRH–KLH) and GonaCon-B
TM
(GnRH–blue protein), were prepared in emulsion form as one-injection
and two-injection immunocontraceptive vaccine formulations. In addi-
tion, the GnRH–KLH protein conjugate was lyophilized and suspended
in AdjuVac
TM
adjuvant to produce a fifth vaccine formulation. Each for-
mulation was administered to a group of five captive adult female
white-tailed deer. Reproductive performance of treated female deer was
monitored for 5 years to determine the comparative efficacy of the vari-
ous treatments.
Results
The longevity of the contraceptive response (2–5 years) was strongly
influenced by the design of the conjugate antigen, the adjuvant used,
and the delivery form of the vaccine.
Conclusion
One-injection and two-injection formulations of GonaCon
TM
and Gona-
Con-B
TM
produced multi-year contraception in adult female white-tailed
deer. GonaCon-B
TM
provided a longer lasting contraceptive effect.
ORIGINAL ARTICLE
Journal compilation ª 2008 Blackwell Munksgaard
214 No claim to original US government works
(Bison bison),9 domestic cats (Felis catus),10 California
ground squirrels (Spermophilus beecheyi),11 and Nor-
way rats (Rattus norvegicus).12
Immunocontraceptive vaccines based on porcine
zona pellucida (PZP) and gonadotropin-releasing
hormone (GnRH) control fertility by stimulating the
production of antibodies that bioneutralize proteins
or hormones essential for conception. PZP immuno-
contraceptive vaccines have been widely tested in
white-tailed deer2,13,14 and other wildlife species.15,16
Female white-tailed deer vaccinated with PZP may
cycle repeatedly and mate several times during the
breeding season while still remaining infertile.17 The
multi-cycling problem associated with PZP vaccines
prompted investigation into the potential use of
GnRH as a contraceptive vaccine.
Gonadotropin-releasing hormone is produced and
secreted by the hypothalamus and is responsible for
the release of two pituitary hormones, follicle-stimu-
lating hormone (FSH) and luteinizing hormone
(LH), and the subsequent release of hormones that
control the functioning of the ovaries and testes.
Antibodies to GnRH induce infertility by binding to
circulating endogenous GnRH and preventing the
GnRH from binding to pituitary receptors, thereby
precluding the release of FSH and LH. The severe
reduction or absence of FSH and LH in the blood-
stream leads to atrophy of the gonads and concomi-
tant infertility in both sexes. Immunoneutralization
of endogenous GnRH through the introduction of a
GnRH conjugate in a vaccine appears to be highly
specific, and does not appear to affect other hypo-
thalamic-releasing hormones.18
An ultimate objective of efforts to develop infertil-
ity agents such as immunocontraceptive vaccines is
the application of these materials to overabundant
populations of free-ranging wildlife to slow the
growth of such populations. Much of the early
research effort to use GnRH immunization as an
infertility method was focused on the contraception
of males.19–21 Reduction of population growth via
contraception would be most effectively accom-
plished by targeting females, however, so most of
our studies have dealt with the use of GnRH vaccine
to induce infertility in females.
In this paper we describe the use of a newly devel-
oped GnRH vaccine in captive, adult, female white-
tailed deer. We also describe recent improvements to
the vaccine including (i) development of a single-
injection technology that provides a multi-year con-
traceptive effect, (ii) development of a new adjuvant
to replace Freund’s
TM
adjuvant, and (iii) replacement
of keyhole limpet hemocyanin (KLH) as a protein
carrier molecule with a more cost-effective mollusk
protein (‘blue protein’) for conjugation with synthetic
GnRH peptide. All of these improvements contrib-
uted to the development of a more effective and
practical contraceptive vaccine for use in wildlife.
Materials and methods
Deer Research Center at Pennsylvania State
University
White-tailed deer used in these studies were born,
raised, and maintained at the Pennsylvania State Uni-
versity (PSU) Deer Research Center, where a captive
deer herd has been maintained since 1972. The origi-
nal source of animals for the PSU deer herd was the
wild white-tailed deer population in central Pennsyl-
vania. Supplements to the PSU captive deer herd
occurred approximately every 5 years until 1996.
Since then, the PSU Deer Research Center has main-
tained a closed herd. During our study, the PSU deer
facility encompassed 22 acres of natural wood-
land ⁄ forest habitat, which were divided into nine
separate paddock areas that ranged in size from 0.12
to 1.54 ha (0.3–3.8 acres). Vegetation on the open
areas consisted of a mixture of clover and orchard
grasses, but most of the land was covered with dense
eastern deciduous forest that had little understory
vegetation. Deer were kept in outdoor paddocks at a
density of 25–37 animals per hectare (10–15 animals
per acre). During the non-breeding portion of the
year, treated female deer were isolated from males.
To test vaccine contraceptive efficacy, however, each
year, from the first week of November through the
end of the following February, four bucks of proven
sire ability in the control herd were confined with the
aggregated females from all five vaccine treatment
groups. The animal facility at the PSU Deer Research
Center was accredited by the Association for the
Assessment and Accreditation of Laboratory Animal
Care (AAALAC). Our study was approved by the
Institutional Animal Care and Use Committee of PSU.
Development of the One-shot GnRH Vaccine
The GonaCon
TM
Immunocontraceptive Vaccine for-
mulations used in this study consisted of synthetic
GnRH peptide conjugated to one of two mollusk
hemocyanins: KLH (Megathura crenulata) or blue
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protein hemocyanin (Concholepas concholepas). Each
1.0-mL dose contained 850 or 1000 lg of the
GnRH-mollusk hemocyanin conjugate. Four differ-
ent treatments resulted from combinations of the
two amounts of conjugate and the two protein
carriers. A fifth treatment consisted of 1000 lg of
the GnRH–KLH conjugate that was lyophilized and
then suspended in AdjuVac
TM
adjuvant.
The Peptide (Hapten)
The Gonadotropin-releasing hormone used in this
study was synthesized at Global Peptide Services
(Fort Collins, CO, USA), with the structure [pE-
HWSYGLRPGGC-SH]. The underlined amino acids
represent the native GnRH molecule. The 10-amino-
acid GnRH peptide hormone was made immunogenic
by coupling it to a large carrier protein that contained
numerous T-cell epitopes. Immune responses to the
GnRH peptide vary with the coupling position of
the GnRH molecule.22–24 A glycine (G) was added at
the C terminus as a spacer, followed by a cysteine
(C) to ensure consistent alignment of the peptide to
the maleimide-activated protein carrier KLH. This
GnRH analog, called GnRH-glycys, has a conforma-
tion similar to that of native GnRH.25
Mollusk Hemocyanin Protein Carrier
GnRH is a small peptide hormone that is not natu-
rally immunogenic. It becomes immunogenic when
it is conjugated to a large carrier protein that con-
tains numerous T-cell epitopes. Carrier proteins used
in vaccine production include tetanus toxoid,21 diph-
theria toxoid,26 bovine serum albumin (BSA), oval-
bumin, and KLH.22,25 BSA is not a good carrier for
use in cattle or deer because of the phylogenetic
proximity between cattle and deer. Our vaccine for-
mulations incorporated the mollusk hemocyanin
proteins KLH (Pierce Chemical, Rockford, IL, USA)
and ‘blue protein’ (Biosonda, Santiago, Chile). These
mollusk proteins are highly immunogenic in mam-
mals because of their large sizes (molecular weights
of 6–8 million), and because the mollusks are phylo-
genetically distant from the vertebrate target species.
Optimal Conjugate Design
Bachmann et al.27 showed that the design of the
immunogen is a critical factor in obtaining a strong
B-cell response to an individual epitope. In a review
of studies of immune responses to hepatitis B vac-
cines, Banatvala et al.28 reported that the strength of
the primary response is influenced by the antigen
dose and structure, and that stronger primary
responses result in longer lasting immune memory.
To make the conjugate used in our vaccine highly
immunogenic, we dissolved the hemocyanin pro-
teins in a 7.5-pH, high-salt buffer that kept the large
molecules intact so that coupling would occur on
their surfaces. The coupling of as many as 300 GnRH
peptide molecules on the surface of a mollusk pro-
tein mimicked the immune image of many patho-
gens, including viruses and bacteria that exhibit
rigid, highly organized, highly repetitive protein
epitopes. This mimicry of the repetitive nature of
pathogen epitopes is an important aspect of the
GnRH-hemocyanin conjugate design. Consistent
alignment of the peptide facilitates the coupling of
the immunogenic protein to the sulfhydryl group of
the terminal amino acid and leaves the 10-amino-
acid GnRH peptide exposed to the immune system.
Before the GnRH peptide can be coupled to the
carrier protein, the carrier protein must be activated
so that the available maleimide groups on the carrier
protein can react with the terminal sulfhydryl-
containing peptides on the GnRH peptide. KLH
purchased from Pierce Chemical was pre-activated
Imject (Pierce Biotechnology Inc., Rockford, IL,
USA) maleimide-activated mcKLH. Our conjugation
process followed Pierce Chemical’s recommended
procedure with minor modifications. Our primary
modification reduced the quantity of GnRH from the
recommended GnRH:KLH ratio of 50:50 to 30:70,
thus reducing the quantity of excess free GnRH
remaining in solution after conjugation.
Blue protein was not maleimide activated when
purchased from Biosonda. Maleimide activation was
accomplished using sulfo-SMCC purchased from
Pierce Chemical. To conjugate the GnRH peptide to
the maleimide-activated mollusk protein, we fol-
lowed the Pierce Chemical instructions except that
we changed the ratio of blue protein to GnRH just as
we did in the GnRH–KLH procedure.
Adjuvant Design – AdjuVac
TM
An important component of any vaccine is a non-
specific immune stimulant called the adjuvant. A
widely used adjuvant is Freund’s Complete Adjuvant
(FCA; Difco Laboratories, Detroit, MI, USA), which
induces strong and long-lasting immunity to a broad
MILLER ET AL.
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range of antigens.29 Concerns over FCA’s severe
injection-site reactions and its potential carcinogenic-
ity, however, prompted NWRC scientists to develop
a new adjuvant by modifying the USDA-licensed
Johne’s vaccine, Mycopar
TM
(Fort Dodge Animal
Health, Fort Dodge, IA, USA). Mycopar is approved
for use in food animals, thus mitigating the concern
for use in deer that may be hunted for human
consumption.
The new adjuvant, called AdjuVac, contains a
small quantity of killed Mycobacterium avium, a com-
mon bacterium found in many species of wildlife
and domestic animals throughout the world.30–32
Because M. avium is widely distributed in natural
environments,33–35 many animals have been
exposed to it, and for that reason they may respond
to the bacterium in AdjuVac as a previously encoun-
tered bacterial antigen.
Preparation of the Vaccine Emulsion
The creation of a depot at the vaccine injection site
may promote a long-lasting immune response
through the slow release of antigen.36,37 To produce
a depot effect, we prepared our vaccine as an emul-
sion. This was accomplished through the dropwise
addition of 0.5 mL of the GnRH-carrier protein con-
jugate in mollusk-stabilizing buffer (MSB) to 0.5 mL
of AdjuVac adjuvant with vigorous vortexing. The
emulsion was stiffened by passing it through a
22-gauge needle three times.
Animal Handling, Vaccination, and Sample
Collection
Twenty female deer were divided into four treatment
groups with five deer per group. Four preparations
were tested (i) GnRH–KLH-AdjuVac (850 lg one-
shot), (ii) GnRH–KLH-AdjuVac (1000 lg ⁄ 1000 lg
two-shot), (iii) GnRH–blue protein-AdjuVac (1000 lg
one-shot), and (iv) GnRH–KLH-AdjuVac (1000-lg lyo-
philized suspension).
Prior to handling and vaccination, animals were
sedated with Xylazine
TM
(100 mg ⁄ mL; Bayer, Lever-
kusen, North Rhine-Westphalia, Germany), which
was administered intramuscularly (i.m.) at 2.2–
4.4 mg ⁄ kg (depending upon the nervousness of the
individual animal). Each deer was then given an i.m.,
hand-injected dose of 1.0 mL of one of the vaccine
preparations. Each injection was delivered to the
right hindquarter with a 3 mL syringe and a 2.54 cm
(1-inch), 19-gauge, hypodermic needle. The sedative
effect was then reversed with Tolazine
TM
(100 mg ⁄ mL;
Lloyd Inc., Shenandoah, IA, USA) administered
intravenously (i.v.) or i.m. at 4.0 mg ⁄ kg.
Blood samples were taken before vaccination in
July and then again during September, October and
February each year. Approximately 7–10 mL of
blood was collected from the jugular vein with
10-mL vacutainer blood collection tubes and 2.54 cm
(1-inch), 18-gauge needles (Becton Dickinson,
Franklin Lakes, NJ, USA). Blood samples were cen-
trifuged and serum was isolated and then stored at
)70C. During the first week of February each year,
a blood sample was collected and centrifuged, and
the serum was evaluated for progesterone and anti-
GnRH antibody titers. At the same time in February,
ultrasound examinations were performed to deter-
mine if the does were pregnant. Ultimate reproduc-
tive efficacy was assessed by evaluating annual fawn
production.
Laboratory Testing
Progesterone
The Coat-A-Count Progesterone In-vitro Diagnostic
Test Kit
TM
(Diagnostic Products, Los Angeles, CA,
USA) was used in these studies according to the
manufacturer’s recommended procedure. For each
test, we used 0.1 mL of serum.
Anti-GnRH antibody titers
The enzyme-linked immunosorbent assay (ELISA)
was used to measure anti-GnRH antibody titers.
Fifty microlitres of serum was used for each assay.
A 96-well plate was prepared by adding 100 ng of
BSA-GnRH antigen to each well and then block-
ing with SeaBlock
TM
from Pierce Chemical. As either
KLH-GnRH or blue protein-GnRH was used in the
vaccine, BSA-GnRH was added to the ELISA plate,
causing only antibodies to GnRH to be detected.
Deer blood serum was serially diluted from 1:1000
to 1:128,000 in phosphate-buffered saline containing
SeaBlock. Antibodies in the deer serum to GnRH on
the plate were directed with the following linkages:
deer anti-GnRH bound to GnRH on the plate, rabbit
anti-deer IgG bound to the deer IgG, and goat anti-
rabbit-peroxidase bound to the rabbit IgG. Chromo-
gen tetramethylbenzidine was used to develop the
color, and 2 m H2SO4 was used to stop the reaction.
The color intensity of the sample was read at
450 nm with a Dynatech MR 5000 ELISA plate
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reader (Dynatech Laboratories, Alexandria, VA,
USA).
Contraceptive efficacy: The mean reproductive success
of the entire PSU captive deer herd was used as a
control value that was compared with that of the
GnRH-treated deer. Deer intentionally bred at the
PSU facility during the period 1994–1998 produced
an average of 1.7 fawns per year.2 The deer in the
current study were managed at the same facility and
were maintained under conditions similar to those
during the earlier period. In this study, if a vacci-
nated doe bore twins, she was physically removed
from the treatment group (to reduce animal mainte-
nance costs), but she was retained in our data analy-
sis with the assumption that she would have
remained fertile for the remainder of the study.
Treated does that bore single fawns remained in the
treatment groups.
Results
Group 1: GnRH–KLH-AdjuVac
TM
(850 lg one-shot)
All five does vaccinated in July 2000 with the for-
mulation of GonaCon
TM
that contained KLH (850 lg
single-shot) were infertile during the 2000–2001
breeding season (Table I). A year later, three of the
five does (60%) remained infertile, whereas the
remaining two treated does each bore a single
fawn. One of the infertile does died in July 2002,
leaving four deer remaining in the treatment group.
One of the fertile does that produced a fawn in
2002 bore twins in 2003 and was then physically
removed from the treatment group. In our analysis,
however, we assumed that, in the absence of revac-
cination, she would have remained fertile through-
out the rest of the study. Of the two remaining
infertile does, only one produced a fawn (during
2005).
Group 2: GnRH–KLH-AdjuVac
TM
(1000 lg ⁄ 1000 lg
two-shot)
For 2 years, all five does in this treatment group
were infertile. During the third year, four does
remained infertile, and during the fourth year, three
remained infertile (Table I).
Group 3: GnRH–blue protein-AdjuVac
TM
(1000 lg
one-shot)
All five treated does remained infertile through the
first 2 years of the study (Table I). During each of
the third and fourth years, only one of five does
became pregnant. Interestingly, one doe produced a
single fawn in the third season, but did not repro-
duce during the following year. Another doe that
had been infertile for the first three breeding seasons
produced a single fawn during the fourth season.
Although she was then given a booster vaccine dose
(same formulation as the primary dose) that caused
her to be infertile during the fifth year of the study,
we assumed for the purposes of our analysis that she
would have remained fertile in year five had she not
been revaccinated.
Group 4: GnRH–KLH-AdjuVac
TM
(1000 lg
lyophilized suspension)
The GnRH–KLH vaccine given as a lyophilized sus-
pension did not provide a long-lasting immune
response. Only two of the five deer in this treatment
group developed a sufficiently strong antibody
response to achieve infertility during the first year
(Table I). Titers in these two does dropped below
contraceptive level (antibody levels ‡1:64,000 gener-
ally are associated with infertility in adult white-
tailed deer2) during the second year, when all five
does became pregnant (Fig. 1, Table I). Hence, the
trial was terminated.
Table I Contraceptive Efficacy of Four GnRH Vaccine
Formulations Given to Captive Adult Female White-Tailed Deer
Treatment group
Year post-treatment
1 2 3 4 5
GnRH–KLH one-shot 100 60 50a 50 25
GnRH–KLH two-shot 100 100 80 60 n ⁄ ab
GnRH–blue one-shot 100 100 80 80 80
GnRH–KLH lyophilized
one-shot
40 0 n ⁄ ab n ⁄ ab n ⁄ ab
All vaccine formulations were emulsions except the lyophilized
formulation, which was a suspension. Table values are the per-
centages of treated deer that were infertile each year. Five deer
were injected with each vaccine formulation.
GnRH, gonadotropin-releasing hormone; KLH, keyhole limpet
hemocyanin.
aOne doe died during previous year, leaving n = 4.
bTreatment group was removed from study.
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Serum Progesterone Concentrations and
Ultrasound Examinations
Except in the deer treated with the lyophilized sus-
pension (group 4), serum progesterone concentra-
tions were generally low in treated deer throughout
the study (Figs 2–4). Progesterone levels assayed on
serum drawn each February had a strong, positive
correlation with spring fawning. Multiple studies
have demonstrated that GnRH contracepted deer
have serum progesterone concentrations of
<1.5 ng ⁄ mL in the month of February while controls
and deer that are no longer contracepted by GnRH
have concentrations >3.0 ng ⁄ mL. In this study using
Fig. 1 Gonadotropin-releasing hormone–keyhole limpet hemocyanin
lyophilized suspension, one-shot. A single injection (1000 lg) of this
GonaCon
TM
vaccine formulation was given to five captive adult female
white-tailed deer during July 2002. The GnRH–KLH conjugate was
lyophilized and made into a suspension with the oil-based adjuvant
AdjuVac
TM
. A contraceptive effect was induced only in two deer by
this vaccine, and it lasted for only 1 year, as reflected in the elevated
blood serum progesterone concentrations observed in February 2003
and 2004, as well as in the low anti-GnRH antibody titers, especially
after 2002. When vaccine efficacy reached zero during 2004, this trial
was terminated.
Fig. 2 Gonadotropin-releasing hormone–keyhole limpet hemocyanin
emulsion, one-shot. A single injection (850 lg) of this GonaCon
TM
vac-
cine formulation was given to five captive adult female white-tailed
deer during July 2000. The GnRH–KLH conjugate was made into an
emulsion with the oil-based adjuvant AdjuVac
TM
. An initially strong
immune response, as indicated by high anti-GnRH antibody titers,
resulted in the contraception of all five deer during the first year after
vaccination. The immune response declined during the second year
and then remained fairly stable throughout the remainder of the
4.5-year trial.
Fig. 3 Gonadotropin-releasing hormone–keyhole limpet hemocyanin
emulsion, two-shot. A primary injection (1000 lg) of this GonaCon
TM
vaccine formulation was given to five captive adult female white-tailed
deer during July 2002, and a booster injection (1000 lg) was given
during September 2002. The GnRH–KLH conjugate was made into an
emulsion with the oil-based adjuvant AdjuVac
TM
. Elevated anti-GnRH
antibody titers persisted until 2004, when an apparent self-boosting
effect re-elevated the titers. The low blood serum progesterone con-
centrations observed in deer in this treatment group throughout the
3.5-year trial were associated with a lack of cycling and pregnancy.
Fig. 4 Gonadotropin-releasing hormone–blue protein emulsion, one-
shot. A single injection (1000 lg) of this GonaCon-B
TM
vaccine formula-
tion was given to five captive adult female white-tailed deer during
July 2002. The GnRH–blue protein conjugate was made into an emul-
sion with the oil-based adjuvant AdjuVac
TM
. Elevated anti-GnRH anti-
body titers persisted throughout the 3.5-year trial, during which
several apparent self-boosting effects occurred. The low blood serum
progesterone concentrations observed in deer in this treatment group
throughout the trial were associated with a lack of cycling and
pregnancy.
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progesterone concentrations of >3.0 ng ⁄ mL as a
positive indicator of pregnancy, we found that the
correlation between elevated progesterone and
spring fawning was 0.90 (r2 = 0.95, P < 0.0001).
Ultrasound performed at the same time also had a
high correlation with spring fawning (r2 = 0.95,
P < 0.0001).
Anti-GnRH Antibody Titers
An examination of the anti-GnRH antibody titers
measured in deer in the various treatment groups
(Figs 1–4) and the corresponding contraceptive
effects (Table I) indicated that these factors were
directly related. The 850 lg, single-shot KLH treat-
ment produced initially high antibody titers and con-
traception in all five does during the first year after
vaccination (Fig. 2). The decline in antibody levels
during the second and subsequent years, however,
corresponded with a decline in the contraceptive
rate. In vaccine trial 2, the 1000 lg ⁄ 1000 lg KLH
primary and booster doses provided a much longer
lasting antibody response (Fig. 3), which produced
longer lasting contraceptive effects (Table I). The
replacement of KLH by the blue protein carrier pro-
duced an immune response with a single injection
that was stronger than that observed in response to
the KLH two-shot treatment (Figs 3 and 4). This
strong antibody response produced a 5-year contra-
ceptive effect in four of five blue protein-treated
does (Table I). On the other hand, the use of
1000 lg of GnRH–KLH conjugate, lyophilized and
suspended in AdjuVac, provided only a weak, short-
term immune response (Fig. 1). Only two of five
does were infertile during the first year after vacci-
nation, and, as antibody titers declined during the
second year, all five does became pregnant (Fig. 1,
Table I).
Discussion
GonaCon
TM
Immunocontraceptive Vaccine sup-
presses reproductive activity in female white-tailed
deer, and may be effective in reducing undesirable
behavior associated with the autumn breeding per-
iod or rut. PZP vaccines, on the other hand, may
actually increase the incidence of such behavior by
extending the duration of the breeding sea-
son.17,38,39 By lengthening the rut, PZP vaccines
are likely to increase rut-associated movements of
deer, thereby increasing the occurrence of deer–
vehicle collisions. On the other hand, two-shot for-
mulations of GnRH-based vaccines such as Gona-
Con
TM
have limited potential for practical
application as wildlife contraceptive agents, and
the Freund’s
TM
adjuvant used in early formulations
of GnRH vaccines caused large injection-site
granulomas.40 The development of a non-Freund’s,
single-injection immunocontraceptive vaccine rep-
resents an important breakthrough in wildlife
contraception.
Several factors were involved in the production
of this single-injection, multi-year vaccine. It has
been known for more than 20 years that to pro-
duce antibody to GnRH, the peptide must be cou-
pled to a larger protein. Many different proteins
and coupling techniques have been used (as dis-
cussed in the Materials and methods section), but in
many cases, much of the resultant antibody pro-
duction targeted the carrier protein and not the
GnRH peptide. Therefore the vaccines required
a primary and several booster doses to produce a
6-month-long response.21,26,41
In our conjugate, the mollusk protein remained
intact because of the presence of a stabilizing buffer,
and the GnRH peptide coupled to the surface of the
carrier molecule. The immune response of the target
animal was highly directed to the repeating GnRH
peptides on the surface. This directed response pro-
vided a strong antibody response to a normally
small, non-immunogenic peptide.
Factors Essential for a Multi-year Response to a
Single Vaccine Injection
Emulsion form of delivery
The longevity of the contraceptive response appears
to be related to the delivery of the antigen in an
emulsion form. A properly prepared emulsion is sta-
ble at 4C for months to years; if the emulsion is not
prepared properly, it may begin to separate within
weeks.42 A poor emulsification would preclude the
long-term effectiveness of the vaccine. The need to
produce a stable emulsion is probably related to the
need for a depot effect at the injection site to provide
a slow release of the antigen. Although lyophiliza-
tion of the GnRH-mollusk hemocyanin conjugate
and addition of the lyophilized antigen to the Adju-
Vac
TM
adjuvant in a suspension form did not provide
a long-term, single-injection contraceptive effect
(Table I), lyophilized delivery may be effective in a
two-shot form.
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Presence of Mycobacterium avium in AdjuVac
GonaCon
TM
vaccine is a mixture of a new, highly
immunogenic antigen (GnRH-mollusk hemocyanin)
with a previously experienced M. avium bacterium.
In a GnRH vaccine study with black-tailed deer (Odo-
coileus hemionus columbianus), Perry et al.43 injected a
group of deer with GnRH vaccine in which M. avium
had been replaced by DD-Dextran in the adjuvant.
The first-year response to the DD-Dextran was 14%
contraception (n = 14). The deer were revaccinated
during the following year, resulting in a 90% contra-
ception rate. In the same study, deer (n = 8) given a
single injection of GonaCon
TM
vaccine that contained
M. avium exhibited contraception rates of 79% dur-
ing the first year after vaccination, and 75% during
the second year.43
Self boosting: follicular dendritic cells provide continued
presence of antigen
The antibody titers illustrated in Figs 2–4 indicate that
self-boosting of the GnRH antibody is essential for the
single-injection, multi-year contraceptive effect. Fol-
licular dendritic cells (FDC) in the lymph node that
drains the site of injection may provide the basis for
the long-term immune response associated with some
antigens. An immunoglobulin G (IgG) antibody
needed for an immunocontraceptive response has a
half-life of 23 days.44 Although antigen-specific mem-
ory B-cells are produced with an initial immunization,
the induction of immunocontraception that persists
for months or years requires a repeated stimulation of
these B-cells by the injected antigen.
The long-term immune response is thought to be
dependent on the formation of immune-complexes
(ICs). In the two-dose paradigm, specific antibodies
produced by the primary dose are present at the
time of injection of the second dose of antigen,
resulting in the formation of ICs. The second dose of
antigen selects for the higher affinity antibody-pro-
ducing B-cells. The higher affinity antibodies are
more likely to bind to the target antigen. Affinity
maturation of the antibody occurs gradually as new
memory B-cells are selected by exposure to small
(picogram) quantities of retained antigen.
To be effective in producing long-lasting antibod-
ies, antigen administered in a single dose must be
retained in the body long enough to produce specific
antibodies that will bind with the antigen to form
ICs. These ICs could then bind FDCs, protecting the
antigen from macrophage and liver degradation.
ICs may begin to form within 7–14 days after a
primary injection, or within minutes after a booster
injection.45
The presence of a specific antibody is the signifi-
cant difference between primary and secondary anti-
body responses, as the specific antibody from the
primary response combines with the antigen to form
immune complexes for transport into draining sec-
ondary lymphoid tissues. Many of these immune
complexes are eliminated by phagocytic cells, but
some are trapped on the surface of FDC for months
to years.27,46
In the absence of specific antibody, soluble antigen
freely diffuses through the draining lymph nodes and
interacts with the appropriate immune cells.45 Initial
clearance of antigen is because of catabolism.45 By
the fourth day, there is enough specific antibody to
begin a second phase of immune clearance, in which
antigen complexes with specific antibody are cleared
by macrophages in the afferent and efferent sinuses
of the lymph nodes, the sinusoids of the liver, and
the marginal sinuses of the spleen.46,47 FDC trap
immune complexes and retain picogram amounts of
antigen on their surfaces for long periods.45
Antigen availability to the immune system is highly
regulated throughout this process. Low levels of spe-
cific antigen induce antigen release from FDC, and
high antibody concentration inhibits the release of
antigen.45 High concentrations of antibody interact
with the antigen on FDC processes and crosslink them
so that the antigen is not available to the surrounding
cells.45 In addition, it appears that the antigen released
from FDC is significantly more immunogenic than
free antigen, such that it may take 1000 pg of free
antigen to elicit antibody production, whereas it takes
only 10 pg of FDC-retained antigen to elicit the same
response.48 This greater immunogenicity may also be
caused by the proximity of the antigen-containing
FDC and the B-cells in the draining lymph nodes.
Conclusions
GonaCon
TM
Immunocontraceptive Vaccine is a highly
effective, single-injection, multi-year contraceptive
agent based on conjugated GnRH–KLH or GnRH–
blue protein. Although both formulations of the vac-
cine caused infertility in female white-tailed deer,
GonaCon-B
TM
, which incorporates the GnRH–blue
protein conjugate, was a more effective, longer lasting,
and more economical contraceptive agent than the
GnRH–KLH formulation. Both conjugate formu-
lations of GonaCon
TM
vaccine used the adjuvant
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AdjuVac
TM
in an emulsion that was injected into the
hind limb musculature of the target animal, and
both were effective as a single-injection contracep-
tive agent in captive adult female white-tailed deer.
Vaccine delivered as a lyophilized suspension is not
as effective when compared to the emulsion form of
delivery.
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